Tigecycline: in-vitro performance as a predictor of clinical efficacy

This publication has 53 references indexed in Scilit:

• Overview of Nosocomial Infections Caused by Gram-Negative Bacilli
  Clinical Infectious Diseases, 2005
• CTX-M: changing the face of ESBLs in the UK
  Journal of Antimicrobial Chemotherapy, 2005
• Antimicrobial Resistance Trends and Outbreak Frequency in United States Hospitals
  Clinical Infectious Diseases, 2004
• Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Community and Private Health Care Centers
  Antimicrobial Agents and Chemotherapy, 2003
• Bacterial Resistance: Origins, Epidemiology, and Impact
  Clinical Infectious Diseases, 2003
• Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936)
  Journal of Antimicrobial Chemotherapy, 2002
• In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases
  Diagnostic Microbiology and Infectious Disease, 2001
• Resistance Patterns Among Nosocomial Pathogens
  Chest, 2001
• In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae
  Diagnostic Microbiology and Infectious Disease, 2000
• In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria
  Antimicrobial Agents and Chemotherapy, 2000